Faheem Hasnain Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Faheem Hasnain.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Faheem Hasnain. Faheem Hasnain is EVP, Oncology/Rheumatology SBU in BIOGEN INC. ($IDPH) and SVP, Oncology SBU in BIOGEN INC. ($IDPH) and Director in VITAL THERAPIES INC ($VTL) and Director in Tocagen Inc ($TOCA) and Director in Kura Oncology, Inc. ($KURA) and President & CEO in Receptos, Inc. ($RCPT) and in Mirati Therapeutics, Inc. ($MYG) and Director in Gossamer Bio, Inc. ($GOSS) and Executive Chairman in Gossamer Bio, Inc. ($GOSS) and President & CEO in Gossamer Bio, Inc. ($GOSS) and Director in Nuvation Bio Inc. ($PANA).
Latest Insider Trading Transactions of Faheem Hasnain
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, IDPH, TOCA, GOSS, VTL, KURA, MYG, NUVB, RCPT
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 23 2021 | KURA | Kura Oncology, Inc ... | Hasnain Faheem | Director | Option Exercise | A | 21.54 | 23,000 | 495,420 | 23,000 | |
| Mar 01 2021 | GOSS | Gossamer Bio, Inc. | Hasnain Faheem | President & CEO | Option Exercise | A | 9.79 | 325,000 | 3,181,750 | 325,000 | |
| Mar 01 2021 | GOSS | Gossamer Bio, Inc. | Hasnain Faheem | President & CEO | Grant | A | 0.00 | 162,500 | 0 | 162,500 | 0 to 162.5 K |
| Feb 26 2021 | PANA | Nuvation Bio Inc. | Hasnain Faheem | Director | Option Exercise | M | 0.00 | 25,000 | 0 | 0 | |
| Feb 26 2021 | PANA | Nuvation Bio Inc. | Hasnain Faheem | Director | Grant | A | 10.00 | 30,000 | 300,000 | 55,000 | 25 K to 55 K (+120.00 %) |
| Feb 26 2021 | PANA | Nuvation Bio Inc. | Hasnain Faheem | Director | Buy | M | 0.00 | 25,000 | 0 | 25,000 | 0 to 25 K |
| Jan 20 2021 | MYG | Mirati Therapeutic ... | Hasnain Faheem | Option Exercise | A | 214.47 | 3,064 | 657,136 | 3,064 | ||
| Jan 20 2021 | MYG | Mirati Therapeutic ... | Hasnain Faheem | Grant | A | 0.00 | 2,098 | 0 | 5,098 | 3 K to 5.1 K (+69.93 %) | |
| Jun 26 2020 | KURA | Kura Oncology, Inc ... | Hasnain Faheem | Director | Option Exercise | A | 17.97 | 23,000 | 413,310 | 23,000 | |
| Jun 18 2020 | GOSS | Gossamer Bio, Inc. | Hasnain Faheem | Director | Option Exercise | A | 12.10 | 47,000 | 568,700 | 47,000 | |
| Jan 07 2020 | MYG | Mirati Therapeutic ... | Hasnain Faheem | Option Exercise | A | 113.20 | 6,000 | 679,200 | 6,000 | ||
| Jan 07 2020 | MYG | Mirati Therapeutic ... | Hasnain Faheem | Grant | A | 0.00 | 3,000 | 0 | 3,000 | 0 to 3 K | |
| Jan 07 2020 | MYG | Mirati Therapeutic ... | Hasnain Faheem | Option Exercise | A | 113.20 | 6,000 | 679,200 | 6,000 | ||
| Jan 07 2020 | MYG | Mirati Therapeutic ... | Hasnain Faheem | Grant | A | 0.00 | 3,000 | 0 | 3,000 | 0 to 3 K | |
| Oct 04 2019 | TOCA | Tocagen Inc | Hasnain Faheem | Director | Option Exercise | A | 0.64 | 7,500 | 4,793 | 7,500 | |
| Oct 04 2019 | TOCA | Tocagen Inc | Hasnain Faheem | Director | Option Exercise | A | 0.64 | 7,500 | 4,793 | 7,500 | |
| Sep 27 2019 | GOSS | Gossamer Bio, Inc. | Hasnain Faheem | Director | Buy | P | 16.80 | 10,000 | 167,980 | 3,382,109 | 3.4 M to 3.4 M (+0.30 %) |
| Jun 27 2019 | KURA | Kura Oncology, Inc ... | Hasnain Faheem | Director | Option Exercise | A | 19.55 | 13,000 | 254,150 | 13,000 | |
| Jun 03 2019 | TOCA | Tocagen Inc | Hasnain Faheem | Director | Buy | P | 5.15 | 250 | 1,287 | 245,857 | 245.6 K to 245.9 K (+0.10 %) |
| Jun 03 2019 | TOCA | Tocagen Inc | Hasnain Faheem | Director | Buy | P | 5.30 | 3,890 | 20,613 | 245,607 | 241.7 K to 245.6 K (+1.61 %) |
| Jun 03 2019 | TOCA | Tocagen Inc | Hasnain Faheem | Director | Buy | P | 4.59 | 38,860 | 178,414 | 241,717 | 202.9 K to 241.7 K (+19.16 %) |
| May 31 2019 | TOCA | Tocagen Inc | Hasnain Faheem | Director | Option Exercise | A | 4.22 | 20,000 | 84,400 | 20,000 | |
| Mar 26 2019 | GOSS | Gossamer Bio, Inc. | Hasnain Faheem | Executive Chairman | Option Exercise | A | 22.10 | 43,500 | 961,350 | 43,500 | |
| Feb 20 2019 | MYG | Mirati Therapeutic ... | Hasnain Faheem | Option Exercise | A | 72.62 | 47,000 | 3,413,140 | 47,000 | ||
| Feb 12 2019 | GOSS | Gossamer Bio, Inc. | Hasnain Faheem | Executive Chairman | Option Exercise | C | 0.00 | 77,719 | 0 | 0 | |
| Feb 12 2019 | GOSS | Gossamer Bio, Inc. | Hasnain Faheem | Executive Chairman | Option Exercise | C | 0.00 | 185,984 | 0 | 0 | |
| Feb 12 2019 | GOSS | Gossamer Bio, Inc. | Hasnain Faheem | Executive Chairman | Buy | C | 0.00 | 58,599 | 0 | 3,372,109 | 3.3 M to 3.4 M (+1.77 %) |
| Sep 17 2018 | VTL | VITAL THERAPIES IN ... | Hasnain Faheem | Director | Sell | S | 0.44 | 118,243 | 51,767 | 4,500 | 122.7 K to 4.5 K (-96.33 %) |
| Sep 17 2018 | VTL | VITAL THERAPIES IN ... | Hasnain Faheem | Director | Sell | S | 0.44 | 59,200 | 25,912 | 122,743 | 181.9 K to 122.7 K (-32.54 %) |
| Sep 17 2018 | VTL | VITAL THERAPIES IN ... | Hasnain Faheem | Director | Sell | S | 0.44 | 118,243 | 51,767 | 4,500 | 122.7 K to 4.5 K (-96.33 %) |
| Sep 17 2018 | VTL | VITAL THERAPIES IN ... | Hasnain Faheem | Director | Sell | S | 0.44 | 59,200 | 25,912 | 122,743 | 181.9 K to 122.7 K (-32.54 %) |
| Jun 25 2018 | TOCA | Tocagen Inc | Hasnain Faheem | Director | Option Exercise | A | 8.98 | 20,000 | 179,600 | 20,000 | |
| Jun 08 2018 | KURA | Kura Oncology, Inc ... | Hasnain Faheem | Director | Option Exercise | A | 16.35 | 13,000 | 212,550 | 13,000 | |
| May 25 2018 | VTL | VITAL THERAPIES IN ... | Hasnain Faheem | Director | Option Exercise | A | 6.10 | 41,353 | 252,253 | 41,353 | |
| Sep 15 2017 | VTL | VITAL THERAPIES IN ... | Hasnain Faheem | Director | Buy | P | 4.19 | 59,200 | 247,870 | 181,943 | 122.7 K to 181.9 K (+48.23 %) |
| Sep 06 2017 | VTL | VITAL THERAPIES IN ... | Hasnain Faheem | Director | Option Exercise | A | 3.15 | 15,222 | 47,949 | 15,222 | |
| Jun 12 2017 | KURA | Kura Oncology, Inc ... | Hasnain Faheem | Director | Option Exercise | A | 8.60 | 10,000 | 86,000 | 10,000 | |
| May 25 2017 | VTL | VITAL THERAPIES IN ... | Hasnain Faheem | Director | Option Exercise | A | 3.20 | 45,022 | 144,070 | 45,022 | |
| Apr 21 2017 | TOCA | Tocagen Inc | Hasnain Faheem | Director | Buy | P | 10.00 | 100,000 | 1,000,000 | 202,857 | 102.9 K to 202.9 K (+97.22 %) |
| Apr 21 2017 | TOCA | Tocagen Inc | Hasnain Faheem | Director | Buy | J | 10.00 | 102,857 | 1,028,570 | 102,857 | 0 to 102.9 K |
| Apr 12 2017 | TOCA | Tocagen Inc | Hasnain Faheem | Director | Option Exercise | A | 10.00 | 10,869 | 108,690 | 10,869 | |
| Aug 15 2016 | VTL | VITAL THERAPIES IN ... | Hasnain Faheem | Director | Option Exercise | A | 5.92 | 58,574 | 346,758 | 58,574 | |
| Aug 15 2016 | VTL | VITAL THERAPIES IN ... | Hasnain Faheem | Director | Buy | P | 5.92 | 118,243 | 699,999 | 122,743 | 4.5 K to 122.7 K (+2,627.62 %) |
| May 13 2016 | KURA | Kura Oncology, Inc ... | Hasnain Faheem | Director | Option Exercise | A | 3.12 | 10,000 | 31,200 | 10,000 | |
| Aug 27 2015 | RCPT | Receptos, Inc. | Hasnain Faheem | President & CEO | Option Exercise | D | 41.51 | 106,107 | 4,404,502 | 0 | |
| Aug 27 2015 | RCPT | Receptos, Inc. | Hasnain Faheem | President & CEO | Option Exercise | D | 18.77 | 143,500 | 2,693,495 | 0 | |
| Aug 27 2015 | RCPT | Receptos, Inc. | Hasnain Faheem | President & CEO | Option Exercise | D | 8.10 | 133,333 | 1,079,997 | 0 | |
| Aug 27 2015 | RCPT | Receptos, Inc. | Hasnain Faheem | President & CEO | Sell | D | 0.00 | 32,500 | 0 | 0 | 32.5 K to 0 (-100.00 %) |
| Aug 27 2015 | RCPT | Receptos, Inc. | Hasnain Faheem | President & CEO | Sell | U | 0.00 | 384,409 | 0 | 32,500 | 416.9 K to 32.5 K (-92.20 %) |
| Apr 27 2015 | KURA | Kura Oncology, Inc ... | Hasnain Faheem | Director | Option Exercise | A | 6.32 | 30,000 | 189,600 | 30,000 | |
| Apr 03 2015 | RCPT | Receptos, Inc. | Hasnain Faheem | President & CEO | Grant | A | 0.00 | 32,500 | 0 | 416,909 | 384.4 K to 416.9 K (+8.45 %) |
| Jul 10 2008 | IDPH | BIOGEN INC. | Hasnain Faheem | EVP, Oncology/Rheum ... | Option Exercise | M | 49.31 | 9,725 | 479,540 | 29,175 | |
| Jul 10 2008 | IDPH | BIOGEN INC. | Hasnain Faheem | EVP, Oncology/Rheum ... | Option Exercise | M | 44.24 | 20,450 | 904,708 | 20,450 | |
| Jul 10 2008 | IDPH | BIOGEN INC. | Hasnain Faheem | EVP, Oncology/Rheum ... | Sell | S | 62.56 | 15,800 | 988,500 | 25,454 | 41.3 K to 25.5 K (-38.30 %) |
| Jul 10 2008 | IDPH | BIOGEN INC. | Hasnain Faheem | EVP, Oncology/Rheum ... | Sell | S | 61.71 | 21,037 | 1,298,105 | 41,254 | 62.3 K to 41.3 K (-33.77 %) |
| Jul 10 2008 | IDPH | BIOGEN INC. | Hasnain Faheem | EVP, Oncology/Rheum ... | Buy | M | 49.31 | 9,725 | 479,540 | 62,291 | 52.6 K to 62.3 K (+18.50 %) |
| Jul 10 2008 | IDPH | BIOGEN INC. | Hasnain Faheem | EVP, Oncology/Rheum ... | Buy | M | 44.24 | 20,450 | 904,708 | 52,566 | 32.1 K to 52.6 K (+63.68 %) |
| Apr 10 2008 | IDPH | BIOGEN INC. | Hasnain Faheem | EVP, Oncology/Rheum ... | Sell | S | 64.94 | 100 | 6,494 | 32,116 | 32.2 K to 32.1 K (-0.31 %) |
| Apr 10 2008 | IDPH | BIOGEN INC. | Hasnain Faheem | EVP, Oncology/Rheum ... | Sell | S | 64.93 | 200 | 12,986 | 32,216 | 32.4 K to 32.2 K (-0.62 %) |
| Apr 10 2008 | IDPH | BIOGEN INC. | Hasnain Faheem | EVP, Oncology/Rheum ... | Sell | S | 64.92 | 100 | 6,492 | 32,416 | 32.5 K to 32.4 K (-0.31 %) |
| Apr 10 2008 | IDPH | BIOGEN INC. | Hasnain Faheem | EVP, Oncology/Rheum ... | Sell | S | 64.82 | 400 | 25,928 | 32,516 | 32.9 K to 32.5 K (-1.22 %) |
| Apr 10 2008 | IDPH | BIOGEN INC. | Hasnain Faheem | EVP, Oncology/Rheum ... | Sell | S | 64.79 | 400 | 25,916 | 32,916 | 33.3 K to 32.9 K (-1.20 %) |
| Apr 10 2008 | IDPH | BIOGEN INC. | Hasnain Faheem | EVP, Oncology/Rheum ... | Sell | S | 64.72 | 300 | 19,416 | 33,316 | 33.6 K to 33.3 K (-0.89 %) |
| Apr 10 2008 | IDPH | BIOGEN INC. | Hasnain Faheem | EVP, Oncology/Rheum ... | Sell | S | 64.67 | 100 | 6,467 | 33,616 | 33.7 K to 33.6 K (-0.30 %) |
| Apr 10 2008 | IDPH | BIOGEN INC. | Hasnain Faheem | EVP, Oncology/Rheum ... | Sell | S | 64.64 | 100 | 6,464 | 33,716 | 33.8 K to 33.7 K (-0.30 %) |
| Apr 10 2008 | IDPH | BIOGEN INC. | Hasnain Faheem | EVP, Oncology/Rheum ... | Sell | S | 64.63 | 300 | 19,389 | 33,816 | 34.1 K to 33.8 K (-0.88 %) |
| Apr 10 2008 | IDPH | BIOGEN INC. | Hasnain Faheem | EVP, Oncology/Rheum ... | Sell | S | 64.61 | 100 | 6,461 | 34,116 | 34.2 K to 34.1 K (-0.29 %) |
| Apr 10 2008 | IDPH | BIOGEN INC. | Hasnain Faheem | EVP, Oncology/Rheum ... | Sell | S | 64.58 | 100 | 6,458 | 34,216 | 34.3 K to 34.2 K (-0.29 %) |
| Apr 10 2008 | IDPH | BIOGEN INC. | Hasnain Faheem | EVP, Oncology/Rheum ... | Sell | S | 64.54 | 100 | 6,454 | 34,316 | 34.4 K to 34.3 K (-0.29 %) |
| Apr 10 2008 | IDPH | BIOGEN INC. | Hasnain Faheem | EVP, Oncology/Rheum ... | Sell | S | 64.51 | 300 | 19,353 | 34,416 | 34.7 K to 34.4 K (-0.86 %) |
| Apr 10 2008 | IDPH | BIOGEN INC. | Hasnain Faheem | EVP, Oncology/Rheum ... | Sell | S | 64.48 | 25 | 1,612 | 34,716 | 34.7 K to 34.7 K (-0.07 %) |
| Apr 10 2008 | IDPH | BIOGEN INC. | Hasnain Faheem | EVP, Oncology/Rheum ... | Sell | S | 64.44 | 800 | 51,552 | 34,741 | 35.5 K to 34.7 K (-2.25 %) |
| Apr 10 2008 | IDPH | BIOGEN INC. | Hasnain Faheem | EVP, Oncology/Rheum ... | Sell | S | 64.42 | 998 | 64,291 | 35,541 | 36.5 K to 35.5 K (-2.73 %) |
| Apr 10 2008 | IDPH | BIOGEN INC. | Hasnain Faheem | EVP, Oncology/Rheum ... | Sell | S | 64.40 | 200 | 12,880 | 36,539 | 36.7 K to 36.5 K (-0.54 %) |
| Apr 10 2008 | IDPH | BIOGEN INC. | Hasnain Faheem | EVP, Oncology/Rheum ... | Sell | S | 64.39 | 2 | 129 | 36,739 | 36.7 K to 36.7 K (-0.01 %) |
| Apr 10 2008 | IDPH | BIOGEN INC. | Hasnain Faheem | EVP, Oncology/Rheum ... | Sell | S | 64.38 | 400 | 25,752 | 36,741 | 37.1 K to 36.7 K (-1.08 %) |
| Apr 10 2008 | IDPH | BIOGEN INC. | Hasnain Faheem | EVP, Oncology/Rheum ... | Sell | S | 64.32 | 500 | 32,160 | 37,141 | 37.6 K to 37.1 K (-1.33 %) |
| Apr 10 2008 | IDPH | BIOGEN INC. | Hasnain Faheem | EVP, Oncology/Rheum ... | Sell | S | 64.18 | 300 | 19,254 | 37,641 | 37.9 K to 37.6 K (-0.79 %) |
| Apr 10 2008 | IDPH | BIOGEN INC. | Hasnain Faheem | EVP, Oncology/Rheum ... | Sell | S | 63.93 | 100 | 6,393 | 37,941 | 38 K to 37.9 K (-0.26 %) |
| Apr 10 2008 | IDPH | BIOGEN INC. | Hasnain Faheem | EVP, Oncology/Rheum ... | Sell | S | 63.89 | 200 | 12,778 | 38,041 | 38.2 K to 38 K (-0.52 %) |
| Apr 10 2008 | IDPH | BIOGEN INC. | Hasnain Faheem | EVP, Oncology/Rheum ... | Sell | S | 63.79 | 200 | 12,758 | 38,241 | 38.4 K to 38.2 K (-0.52 %) |
| Apr 10 2008 | IDPH | BIOGEN INC. | Hasnain Faheem | EVP, Oncology/Rheum ... | Sell | S | 63.71 | 100 | 6,371 | 38,441 | 38.5 K to 38.4 K (-0.26 %) |
| Feb 14 2008 | IDPH | BIOGEN INC. | Hasnain Faheem | EVP, Oncology/Rheum ... | Option Exercise | A | 60.56 | 29,210 | 1,768,958 | 29,210 | |
| Feb 14 2008 | IDPH | BIOGEN INC. | Hasnain Faheem | EVP, Oncology/Rheum ... | Grant | A | 0.00 | 10,430 | 0 | 38,077 | 27.6 K to 38.1 K (+37.73 %) |
| Feb 14 2008 | IDPH | BIOGEN INC. | Hasnain Faheem | EVP, Oncology/Rheum ... | Payment of Exercise | F | 60.56 | 1,788 | 108,281 | 27,647 | 29.4 K to 27.6 K (-6.07 %) |
| Feb 07 2008 | IDPH | BIOGEN INC. | Hasnain Faheem | EVP, Oncology/Rheum ... | Option Exercise | M | 0.00 | 5,467 | 0 | 5,466 | |
| Feb 07 2008 | IDPH | BIOGEN INC. | Hasnain Faheem | EVP, Oncology/Rheum ... | Payment of Exercise | F | 60.52 | 2,017 | 122,069 | 29,435 | 31.5 K to 29.4 K (-6.41 %) |
| Feb 07 2008 | IDPH | BIOGEN INC. | Hasnain Faheem | EVP, Oncology/Rheum ... | Buy | M | 0.00 | 5,467 | 0 | 31,452 | 26 K to 31.5 K (+21.04 %) |
| Nov 02 2007 | IDPH | BIOGEN INC. | Hasnain Faheem | SVP, Oncology SBU | Option Exercise | A | 72.87 | 6,900 | 502,803 | 6,900 | |
| Nov 02 2007 | IDPH | BIOGEN INC. | Hasnain Faheem | SVP, Oncology SBU | Grant | A | 0.00 | 2,700 | 0 | 25,918 | 23.2 K to 25.9 K (+11.63 %) |
| Oct 09 2007 | IDPH | BIOGEN INC. | Hasnain Faheem | SVP, Oncology SBU | Payment of Exercise | F | 65.88 | 3,575 | 235,521 | 23,011 | 26.6 K to 23 K (-13.45 %) |
| May 24 2007 | IDPH | BIOGEN INC. | Hasnain Faheem | SVP, Oncology SBU | Sell | S | 49.00 | 7,446 | 364,854 | 25,897 | 33.3 K to 25.9 K (-22.33 %) |
| Mar 16 2007 | IDPH | BIOGEN INC. | Hasnain Faheem | SVP, Oncology SBU | Payment of Exercise | F | 44.11 | 2,226 | 98,189 | 33,343 | 35.6 K to 33.3 K (-6.26 %) |
| Mar 16 2007 | IDPH | BIOGEN INC. | Hasnain Faheem | SVP, Oncology SBU | Grant | A | 0.00 | 6,225 | 0 | 35,569 | 29.3 K to 35.6 K (+21.21 %) |
| Mar 16 2007 | IDPH | BIOGEN INC. | Hasnain Faheem | SVP, Oncology SBU | Payment of Exercise | F | 44.11 | 2,226 | 98,189 | 33,343 | 35.6 K to 33.3 K (-6.26 %) |
| Mar 16 2007 | IDPH | BIOGEN INC. | Hasnain Faheem | SVP, Oncology SBU | Grant | A | 0.00 | 6,225 | 0 | 35,569 | 29.3 K to 35.6 K (+21.21 %) |
| Feb 14 2007 | IDPH | BIOGEN INC. | Hasnain Faheem | SVP, Oncology SBU | Option Exercise | A | 49.31 | 38,900 | 1,918,159 | 38,900 | |
| Feb 14 2007 | IDPH | BIOGEN INC. | Hasnain Faheem | SVP, Oncology SBU | Grant | A | 0.00 | 15,000 | 0 | 29,344 | 14.3 K to 29.3 K (+104.57 %) |
| Feb 08 2007 | IDPH | BIOGEN INC. | Hasnain Faheem | SVP, Oncology SBU | Option Exercise | D | 0.00 | 5,467 | 0 | 10,933 | |
| Feb 08 2007 | IDPH | BIOGEN INC. | Hasnain Faheem | SVP, Oncology SBU | Payment of Exercise | F | 48.94 | 2,020 | 98,859 | 14,344 | 16.4 K to 14.3 K (-12.34 %) |
| Feb 08 2007 | IDPH | BIOGEN INC. | Hasnain Faheem | SVP, Oncology SBU | Buy | M | 0.00 | 5,467 | 0 | 16,364 | 10.9 K to 16.4 K (+50.17 %) |
| Oct 03 2006 | IDPH | BIOGEN INC. | Hasnain Faheem | SVP, Oncology SBU | Sell | S | 44.70 | 3,244 | 145,007 | 10,793 | 14 K to 10.8 K (-23.11 %) |
| Oct 03 2006 | IDPH | BIOGEN INC. | Hasnain Faheem | SVP, Oncology SBU | Sell | S | 44.63 | 3,000 | 133,890 | 14,037 | 17 K to 14 K (-17.61 %) |
| Oct 03 2006 | IDPH | BIOGEN INC. | Hasnain Faheem | SVP, Oncology SBU | Sell | S | 44.60 | 1,500 | 66,900 | 17,037 | 18.5 K to 17 K (-8.09 %) |
| Oct 03 2006 | IDPH | BIOGEN INC. | Hasnain Faheem | SVP, Oncology SBU | Sell | S | 44.58 | 1,500 | 66,870 | 18,537 | 20 K to 18.5 K (-7.49 %) |
| Oct 03 2006 | IDPH | BIOGEN INC. | Hasnain Faheem | SVP, Oncology SBU | Sell | S | 44.55 | 2,000 | 89,100 | 20,037 | 22 K to 20 K (-9.08 %) |
| Sep 15 2006 | IDPH | BIOGEN INC. | Hasnain Faheem | SVP, Oncology SBU | Payment of Exercise | F | 43.39 | 6,256 | 271,448 | 21,947 | 28.2 K to 21.9 K (-22.18 %) |
| Sep 15 2006 | IDPH | BIOGEN INC. | Hasnain Faheem | SVP, Oncology SBU | Grant | A | 0.00 | 17,500 | 0 | 28,203 | 10.7 K to 28.2 K (+163.51 %) |
| Feb 08 2006 | IDPH | BIOGEN INC. | Hasnain Faheem | SVP, Oncology SBU | Option Exercise | A | 0.00 | 16,400 | 0 | 16,400 | |
| Feb 08 2006 | IDPH | BIOGEN INC. | Hasnain Faheem | SVP, Oncology SBU | Option Exercise | A | 44.24 | 40,900 | 1,809,416 | 40,900 |
Page: 1